<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To evaluate a treatment protocol with repeated transarterial-chemoembolisation (TACE) downsizing before <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-guided laser-induced interstitial thermotherapy (LITT) using different chemotherapeutic combinations in patients with unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Two hundred and twenty-four patients were included in the current study </plain></SENT>
<SENT sid="2" pm="."><plain>Transarterial-chemoembolisation (mean 3.4 sessions per patient) was performed as a downsizing treatment to meet the LITT requirements (number5, diameter &lt;5 cm) </plain></SENT>
<SENT sid="3" pm="."><plain>The intra-arterial protocol consisted of either Irinotecan and <z:chebi fb="0" ids="25357">Mitomycin</z:chebi> (n=77), <z:chebi fb="0" ids="175901">Gemcitabine</z:chebi> and <z:chebi fb="0" ids="25357">Mitomycin</z:chebi> (n=49) or <z:chebi fb="0" ids="25357">Mitomycin</z:chebi> alone (n=98) in addition to Lipiodol and Embocept in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Post TACE, <z:hpo ids='HP_0000001'>all</z:hpo> patients underwent LITT (mean 2.2 sessions per patient) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Overall, TACE resulted in a mean reduction in diameter of the target lesions of 21.4% </plain></SENT>
<SENT sid="6" pm="."><plain>The median time to progression was 8 months, calculated from the start of therapy and the median local <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> control rate was 7.5 months, calculated as of therapy completion </plain></SENT>
<SENT sid="7" pm="."><plain>Median survival of patients calculated from the beginning of TACE was 23 months (range 4-110 months), in patients treated with Irinotecan and <z:chebi fb="0" ids="25357">Mitomycin</z:chebi> the median was 22.5 months, <z:chebi fb="0" ids="175901">Gemcitabine</z:chebi> and <z:chebi fb="0" ids="25357">Mitomycin</z:chebi> 23 months and <z:chebi fb="0" ids="25357">Mitomycin</z:chebi> only 24 months with a statistically significant difference between the groups (P&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Repeated TACE offers adequate downsizing of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> to allow further treatment with LITT </plain></SENT>
<SENT sid="9" pm="."><plain>The combined treatment illustrates substantial survival rates and high local <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> control with statistically significant differences between the three protocols used </plain></SENT>
<SENT sid="10" pm="."><plain>Further randomised trials addressing the current study results are required </plain></SENT>
</text></document>